<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253405</url>
  </required_header>
  <id_info>
    <org_study_id>IP-HCOR/RENOVATEfibrose</org_study_id>
    <nct_id>NCT04253405</nct_id>
  </id_info>
  <brief_title>RENOVATE Fibrosis:HFNC Versus NIPPV in Acute Respiratory Failure in Patients With Pulmonary Fibrosis</brief_title>
  <acronym>Fibrosis</acronym>
  <official_title>Multicentric Randomized Controlled Pilot Study Comparing High Flow Nasal Cannula Versus NonInvasive Positive Pressure Ventilation in Acute Respiratory Failure in Patients With Pulmonary Fibrosis (RENOVATE Fibrosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fisher and Paykel Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot multicentric randomized controlled study investigating the feasibility of recruiting&#xD;
      50 pulmonary fibrosis patients in acute respiratory failure within18 months. Additionally,&#xD;
      exploratory efficacy and safety outcomes will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RENOVATE Fibrosis will recruit patients with pulmonary fibrosis in acute respiratory failure&#xD;
      to be randomized to HFNC or NIPPV. Efficacy and safety outcomes measured are dyspnea&#xD;
      variation, physiological variables (pCO2, respiratory rate, oxygenation), comfort,&#xD;
      endotraqueal intubation rate, mortality in 28 and 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study impacted by the COVID-19 pandemic:&#xD;
&#xD;
      -  slow recruitment rate&#xD;
&#xD;
      -  budget constrains&#xD;
  </why_stopped>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Actual">August 9, 2021</completion_date>
  <primary_completion_date type="Actual">August 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomized controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment feasibility</measure>
    <time_frame>18 months</time_frame>
    <description>Recruitment of 50 pulmonary fibrosis patients in acute respiratory failure in 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspneia variation (Borg scale)</measure>
    <time_frame>7 days</time_frame>
    <description>Borg scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory frequency variation</measure>
    <time_frame>7 days</time_frame>
    <description>Respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) variation</measure>
    <time_frame>7 days</time_frame>
    <description>Oxygen index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon dioxide arterial partial pressure (PaCO2) variation</measure>
    <time_frame>7 days</time_frame>
    <description>CO2 variation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comfort visual analog scale variation</measure>
    <time_frame>7 days</time_frame>
    <description>Confort scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Endotracheal intubation (ETI) rate</measure>
    <time_frame>7 days</time_frame>
    <description>Endotracheal intubation</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Mortality in 28 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality in 90 days</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>High Flow Nasal Cannula (HFNC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The HFNC (Airvo2 Fisher &amp; Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-invasive positive pressure ventilation (NIPPV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or an invasive mechanical ventilator with NIPPV mode are accepted. The interface should be an oronasal or full face mask.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Catheter</intervention_name>
    <description>HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.&#xD;
Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2</description>
    <arm_group_label>High Flow Nasal Cannula (HFNC)</arm_group_label>
    <other_name>Optiflow</other_name>
    <other_name>Airvo</other_name>
    <other_name>trans-nasal insufflation</other_name>
    <other_name>Nasal High Flow</other_name>
    <other_name>High Flow Nasal Cannula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Noninvasive positive pressure ventilation (NIPPV)</intervention_name>
    <description>NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.</description>
    <arm_group_label>Non-invasive positive pressure ventilation (NIPPV)</arm_group_label>
    <other_name>BiPAP</other_name>
    <other_name>Non-invasive ventilation</other_name>
    <other_name>Non-invasive positive pressure ventilation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Sequential adult patients 18 years of age or older admitted to the&#xD;
        hospital with pulmonary fibrosis and acute onset of respiratory failure that meets criteria&#xD;
        A and B bellow.&#xD;
&#xD;
        A. Pulmonary fibrosis will be defined by all of the criteria below:&#xD;
&#xD;
          -  presence of Velcro-type crackles on physical examination&#xD;
&#xD;
          -  imaging compatible with pulmonary fibrosis&#xD;
&#xD;
          -  diffuse disease on imaging&#xD;
&#xD;
        B. Acute respiratory failure (ARF) will be defined by hypoxemia evidenced by SpO2 &lt;90% or&#xD;
        PaO2 &lt;60 mmHg in room air and at least two of the criteria below within the last four&#xD;
        weeks:&#xD;
&#xD;
          -  worsening dyspnea&#xD;
&#xD;
          -  worsening breathing effort&#xD;
&#xD;
          -  worsening gas exchange (worsening SpO2 or paO2)&#xD;
&#xD;
          -  worsening respiratory rate, above 25 irpm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pulmonary fibrosis secondary to progressive massive fibrosis (silicosis), or any other&#xD;
             tumor form of fibrosis;&#xD;
&#xD;
          -  Significant pulmonary arterial hypertension characterized by: Right ventricular&#xD;
             failure on Doppler echocardiogram or Cardiac index &lt;2L / min / m2 in catheterization&#xD;
             of right chambers;&#xD;
&#xD;
          -  Pneumothorax or extensive pleural effusion as the main determinant of ARF in the&#xD;
             assessment of the attending physician;&#xD;
&#xD;
          -  Cardiogenic pulmonary congestion as the main determinant of IRPA in the assessment of&#xD;
             the attending physician;&#xD;
&#xD;
          -  Presence of delirium or non-cooperation at the time of randomization;&#xD;
&#xD;
          -  Anatomical facial abnormalities;&#xD;
&#xD;
          -  Incoercible vomiting or hypersecretion of the airways;&#xD;
&#xD;
          -  Use of continuous VNIPP or HFNC for more than 8h before randomization;&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  Refusal to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leticia Kawano-Dourado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coração</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Israel Maia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coração</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Brasilia (HOBRA)</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital UNIMED Vitória</name>
      <address>
        <city>Vitória</city>
        <state>ES</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia Dante Pazanese</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nereu Ramos</name>
      <address>
        <city>Florianópolis</city>
        <state>SC</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Coracao</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InCor - Hospital das Clinicas da Faculdade de Medicina da USP</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing plan - under construction</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>In 8 months</ipd_time_frame>
    <ipd_access_criteria>Publication</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

